Skip to content

Air-in-Line Alarms During Antineoplastic Drug Infusion

Innovation in Antineoplastic Drug Infusion: A Multiphase Observational Study of Air-in-Line Alarms, Safety, and Therapeutic Continuity

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07718711
Acronym
AIR-ONC
Enrollment
40
Registered
2026-07-22
Start date
2026-07-01
Completion date
2028-06-01
Last updated
2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Air-in-Line Alarm, Antineoplastic Drug Administration, Infusion Safety, Medication Safety

Keywords

Antineoplastic agents, Infusion pumps, Air-in-line alarms, Oncology nursing, High-alert medications, User experience, Infusion safety, Alarm management, Entrustable Professional Activities

Brief summary

The goal of this observational study is to evaluate infusion alarms, particularly air-in-line alarms, during antineoplastic drug infusion in oncology care settings. The main questions it aims to answer are: How frequently do infusion alarms occur, and what types of alarms are observed during antineoplastic drug infusion? How long does it take healthcare professionals to manage infusion alarms and restore infusion continuity? What strategies do healthcare professionals use to manage infusion alarms? How do healthcare professionals evaluate the user experience of different infusion technologies? Participants will be healthcare professionals involved in antineoplastic drug infusion. They will not receive any experimental intervention. Researchers will observe routine infusion procedures and collect data on alarm events, alarm management, infusion technologies, and user experience.

Detailed description

ntravenous administration of antineoplastic drugs represents a complex and high-risk clinical process. Antineoplastic agents are classified as high-alert medications because administration errors may lead to severe clinical consequences. One of the most relevant operational issues in infusion oncology practice is the occurrence of air-in-line alarms, which may interrupt drug administration, increase healthcare professionals' workload, and negatively affect therapeutic continuity. This issue may be particularly relevant with foaming drugs, which are more likely to generate microbubbles within infusion lines. Despite the clinical relevance of infusion alarms, current literature does not provide robust real-world evidence regarding their prevalence, associated factors, or comparative performance of different infusion technologies in oncology settings. Furthermore, limited evidence is available regarding healthcare professionals' operational management of infusion alarms and user experience associated with infusion devices. The present study is designed as a multicenter, prospective, observational, multiphase and multimethod study integrating three complementary methodological phases. Phase 1 consists of a controlled preclinical simulation study using standardized foaming preparations and infusion systems to evaluate the occurrence of air-in-line alarms under simulated conditions. Phase 2 consists of a prospective field observational study aimed at evaluating healthcare professionals' practices during antineoplastic drug infusion and infusion alarm management in real-world oncology settings. This phase applies the Entrustable Professional Activities framework to identify key professional competencies related to infusion safety and alarm management. Phase 3 consists of a prospective multicenter observational cohort study aimed at collecting real-world data regarding infusion alarms, alarm management time, operational strategies, and healthcare professionals' user experience with infusion technologies routinely used in clinical practice. The study does not include experimental interventions, treatment allocation, or modifications to standard clinical practice. All infusion technologies included in the study are CE-marked medical devices routinely used in participating centers according to their intended purpose. No patient clinical data will be collected. Data collection will focus on infusion-related technical events, organizational variables, observable professional behaviors, and healthcare professionals' user experience. The study will be conducted in five Italian oncology centers and is expected to last approximately 24 months following ethics approval and local authorization procedures. Data will be collected and managed using the REDCap electronic data capture platform. Statistical analyses will include descriptive and inferential methods aimed at identifying factors associated with infusion alarm occurrence, alarm management, and user experience outcomes. The results of this study are expected to contribute to the development of evidence-based recommendations for safer infusion practices, optimization of oncology infusion workflows, and improvement of healthcare professionals' training related to infusion technologies and alarm management.

Interventions

OTHERRoutine Infusion Technologies

Observation of routinely used infusion technologies and infusion-related alarm management during standard antineoplastic drug administration in oncology care settings. No experimental intervention or treatment allocation is performed.

Sponsors

Associazione Italiana Infermieri di Area Oncologica
Lead SponsorOTHER
IRCCS Multimedica
CollaboratorOTHER
University of Milan
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Healthcare professionals involved in the administration of antineoplastic drugs in participating oncology centres. * Employment in a participating study site during the study period. * Direct involvement in routine intravenous antineoplastic drug infusion procedures. * Participation in infusion procedures eligible for observation according to the study protocol.

Exclusion criteria

* Healthcare professionals not directly involved in antineoplastic drug administration. * Healthcare professionals working outside participating study sites. * Temporary staff not routinely involved in infusion activities during the observation period. * Refusal to participate in study activities where local regulations require participant notification.

Design outcomes

Primary

MeasureTime frameDescription
Frequency and Type of Infusion AlarmsUp to 24 monthsNumber and type of infusion alarms, including air-in-line alarms, recorded during simulated and real-world antineoplastic infusion procedures.

Secondary

MeasureTime frameDescription
Adherence to Evidence-Based Infusion Safety PracticesUp to 24 monthsObserved adherence to predefined safety behaviors and procedures during antineoplastic drug infusion and infusion alarm management.
User Experience With Infusion TechnologiesUp to 24 monthsHealthcare professionals' user experience scores regarding usability, alarm clarity, perceived safety, workload, confidence, and overall satisfaction with infusion devices.
Operational Strategies for Infusion Alarm ManagementUp to 24 monthsStrategies adopted by healthcare professionals to manage infusion alarms and maintain or restore infusion continuity during antineoplastic drug administration.
Alarm Management TimeUp to 24 monthsTime in minutes required to manage infusion alarms and restore infusion continuity.
Inter-Center Variability in Alarm ManagementUp to 24 monthsVariability in alarm frequency, alarm management time, and operational strategies across participating oncology centers.
Factors Associated With Alarm Occurrence and ManagementUp to 24 monthsClinical, technological, and organisational factors associated with infusion alarm occurrence, alarm management time, and user experience indicators.

Countries

Italy

Contacts

CONTACTRosario Caruso, PhD, RN, FESNO, FAAN
rosario.caruso@unimi.it+ 39 02503 15119
CONTACTGreta Ghizzardi, PhD, RN
greta.ghizzardi@asst-lodi.it+39 0371376565

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026